Editorial
|
|
|
|
|
French regulators in the hot seat
|
|
|
|
Marketing Authorisations
|
|
|
|
|
The drug of first choice
|
|
|
|
|
|
|
|
|
|
Use only in homozygous familial hypercholesterolaemia, with caution
|
|
|
|
|
|
|
|
|
|
No proven advantage in Crohn's disease or ulcerative colitis
|
|
|
|
|
|
Adverse Effects
|
|
|
|
|
Significant impact on patients' quality of life
|
|
|
|
|
|
|
|
|
|
|
|
High-risk situations should be identified
|
|
|
|
|
|
|
|
|
|
|
|
Market withdrawal is required
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Regular warning is needed
|
|
|
|
|
|
Reviews
|
|
|
|
|
Overdiagnosis: an insidious adverse effect of screening
|
|
|
|
|
|
|
|
|
|
Outlook
|
|
|
|
|
A presentation by Marc-André Gagnon, Assistant Professor in public policy at Carleton University (Ottawa, Canada)
|
|
|
|
|
|